Latest Oncology News

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

November 6th 2024

Chandler Park, MD, MSc, FACP

Chandler Park, MD, talks through key updates in genitourinary cancer research from the 2024 ESMO Congress.

Mirdametinib May Provide Long-Awaited Treatment Alternative for Adults/Children With NF1-PNs

Mirdametinib May Provide Long-Awaited Treatment Alternative for Adults/Children With NF1-PNs

November 6th 2024

Courtney Flaherty

Angela Hirbe, MD, PhD, discusses the potential significance of MET inhibitors such as mirdametinib for adult and pediatric patients with NF1-PN.

Zongertinib Research Could Represent Next Wave in HER2-Mutated NSCLC Management

Zongertinib Research Could Represent Next Wave in HER2-Mutated NSCLC Management

November 6th 2024

Ashling Wahner

Christina S. Baik, MD, MS, discusses the types of HER2 testing that should be performed in NSCLC and the design of the phase 3 Beamion LUNG-2 trial.

NICE Advocates Reimbursement for Avapritinib in Aggressive Systemic Mastocytosis, Other Hematologic Malignancies

NICE Advocates Reimbursement for Avapritinib in Aggressive Systemic Mastocytosis, Other Hematologic Malignancies

November 6th 2024

Kyle Doherty

NICE issued a final guidance recommending reimbursement of avapritinib monotherapy in adult patients with ASM, SM-AHN, or mast cell leukemia.

Julia “Julie” Borrelli Named Chair of the Abramson Cancer Center Director's Leadership Council

Julia “Julie” Borrelli Named Chair of the Abramson Cancer Center Director's Leadership Council

November 6th 2024

Sylvester Comprehensive Cancer Center

Julia “Julie” Borrelli has been appointed chair of the Abramson Cancer Center Director's Leadership Council.

Latest Oncology Videos

Dr Baik on the Clinical Utility of Zongertinib in Previously Treated HER2-Mutant NSCLC
Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies
Dr Bardia on Findings From DESTINY-Breast06 in HER2-Low Breast Cancer
Influence of TLS Risk and Patient Preferences on Treatment Selection in Relapsed/Refractory CLL
Key Takeaways for Concurrent Biomarker Testing in NSCLC
Dr Zakalik on the Role of Genetic Testing to Guide Breast Cancer Treatment
Dr Fisher on Mechanisms of Resistance to Pirtobrutinib in CLL
Adopting Broader Clinical Trial Eligibility in Lung Cancer With Brain Mets, Leptomeningeal Disease
Dr Kalinsky on the Future of Treatment With T-DXd in HER2+ Breast Cancer
Dr Montero on Potential Advantages With STX-478 in PI3Kα-Mutant Solid Tumors
Dr Randall on the Effect of Socioeconomic Factors in Pediatric Nonmetastatic Osteosarcoma
Dr Haggstrom on Future Research Directions in EGFR+ and ALK+ NSCLC
Dr Krishnamurthy on Treatment Sequencing Based on Mutation Status in HR+/HER2– Breast Cancer
Dr Lotan on Ongoing Research With Novel Agents in BCG-Unresponsive NMIBC
Dr Westbrook on the Potential Use of ccRCC Therapies in Non-ccRCC
Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01
Application of Pirtobrutinib in R/R CLL: Expert Perspectives
Dr Moore on the Evolving Treatment Landscape for Platinum-Resistant Ovarian Cancer
Best Practices in Managing Patients on Capivasertib
Dr Bekaii-Saab on the Role of Liquid and Tissue Biopsies for Newly Diagnosed GI Cancers
Managing Capivasertib Side Effects: Strategies for Educating, Monitoring, and Addressing Rash and Hyperglycemia
Targeted Therapies and Biomarkers for SCLC: What’s Next on the Horizon
Durvalumab in Endometrial Cancer: DUO-E Trial Updates

All Oncology News

MI Cancer Seek Receives FDA Approval as Companion Diagnostic for Targeted Therapy Across Tumor Types

November 6th 2024

Kyle Doherty

MI Cancer Seek has been granted FDA approval as a companion diagnostic for patients with cancer who may benefit from targeted therapy.

FDA Grants Orphan Drug Designation to LBL-034 for Multiple Myeloma

November 6th 2024

Caroline Seymour

The FDA has granted orphan drug designation to LBL-034 for the treatment of patients with multiple myeloma.

Obinutuzumab and Liso-Cel Revisions to CLL/SLL NCCN Guidelines Mark Most Notable Changes of 2024

November 6th 2024

Megan Hollasch

Matthew Cortese, MD, MPH, details 2024/2025 updates to the NCCN guidelines for CLL/SLL and treatments to look forward to in the future.

Notable 2024/Early 2025 Multiple Myeloma NCCN Guideline Updates Feature Quadruplets and More

November 6th 2024

Megan Hollasch

Shaji Kumar, MD, details key updates/revisions made to the multiple myeloma NCCN guidelines in 2024 and the first version of the 2025 guidelines.

Brahmer's Take: Advancements in 3 Cornerstone Settings of NSCLC

November 6th 2024

Megan Hollasch

Julie R. Brahmer, MD, MSc, FASCO, details practice-changing indications and notable data in the early-stage, neo(adjuvant), and metastatic NSCLC settings.

Indirect Comparison Shows Comparable Efficacy, Improved Safety for Acalabrutinib vs Ibrutinib in R/R Mantle Cell Lymphomal Lymphoma

November 5th 2024

Chris Ryan

An indirect comparison did not show significant differences in survival for acalabrutinib vs ibrutinib in relapsed/refractory mantle cell lymphoma.

Ruxolitinib Plus Pegylated Interferon Alfa-2a Is Safe and Effective in in Newly-Diagnosed PV

November 5th 2024

Courtney Flaherty

Ruxolitinib plus low-dose pegylated interferon alfa-2a is well tolerated and efficacious in patients with newly diagnosed polycythemia vera.

Preoperative Radiotherapy Plus Perioperative Chemo Improves pCR Rate but Not Survival in Resectable Gastric/GEJ Cancer

November 5th 2024

Jax DiEugenio

Trevor Leong, MBBS, MD, FRANZCR, discusses findings from the TOPGEAR trial assessing perioperative chemoradiotherapy in gastric/GEJ cancer.

Cancer Centers Launch Cancer AI Alliance to Unlock Discoveries, Transform Care Using Cancer Data and Applied AI

November 5th 2024

Fred Hutch Cancer Center

AWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with initial funding.

(Z)-endoxifen Reduces MBD, Is Well Tolerated in Premenopausal Women Screened for Breast Cancer

November 5th 2024

Ryan Scott

(Z)-endoxifen significantly reduced mammographic breast density and was generally well tolerated in premenopausal women screened for breast cancer.

Gynecologic Cancer Paradigm Sees Huge Gains With FDA-Approved Regimens

November 5th 2024

Kyle Doherty

Experts in gynecologic oncology highlight multiple practice-altering clinical trial updates presented at ESMO and beyond in ovarian, cervical, and endometrial cancers.

FDA Extends PDUFA Date for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

November 5th 2024

Chris Ryan

The FDA has extended the PDUFA date of the BLA for zenocutuzumab in NRG1-positive non–small cell lung cancer and pancreatic cancer.

OncLive’s October Roundup of Key FDA Approvals in Oncology

November 5th 2024

Kristi Rosa

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

Ongoing Research in Orthopedic Oncology Is Revolutionizing MBD Management

November 5th 2024

Ryan Scott

R. Lor Randall, MD, FACS, discusses research in orthopedic oncology that is revolutionizing the management of metastatic bone disease from primary cancers.

How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEd

November 4th 2024

Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd

Dr Mekhail discusses the rationale for combining chemotherapy with the PD-1 inhibitor toripalimab in patients with nasopharyngeal carcinoma.

See All News